Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.51 |
| ▸ | TACR2 | P21452 | 2/20 | 0.42 |
| ▸ | TACR3 | P29371 | 2/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8566696 | 0.91 | TACR1 (0.52) | TACR1TACR2 | |
| SCHEMBL8970672 | 0.90 | TACR1 (0.47) | TACR1TACR2TACR3CCR5 | |
| SCHEMBL8300796 | 0.83 | TACR1 (0.59) | TACR1TACR2TACR3CCR5 | |
| SCHEMBL7846541 | 0.82 | TACR1 (0.60) | TACR1TACR2TACR3CCR5 | |
| SCHEMBL8569702 | 0.81 | TACR1 (0.48) | TACR1TACR2 | |
| SCHEMBL7817874 | 0.79 | TACR1 (0.54) | TACR1 | |
| SCHEMBL7956549 | 0.78 | TACR1 (0.49) | TACR1CCR5 | |
| SCHEMBL8561467 | 0.77 | TACR1 (0.52) | TACR1TACR2TACR3CCR5 | |
| SCHEMBL8564503 | 0.75 | SLC6A3 (0.37) | TACR1 | |
| SCHEMBL8589071 | 0.74 | TACR1 (0.52) | TACR1TACR2TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5726313-A | Substituted arylaliphatic compounds, method of preparing them and pharmaceutical compositions in which they are present | SANOFI (FR) | 1998-03-10 | — | — | US | disclosed |
| EP-0700386-A1 | NEUROKININ RECEPTOR ANTAGONISTS | SANOFI (FR) | 1996-03-13 | — | — | EP | disclosed |
| WO-1995026338-A1 | NEUROKININ RECEPTOR ANTAGONISTS | SANOFI (FR) | 1995-10-05 | — | — | WO | disclosed |